PAK2 (N-term), 192-222 Antibody from MYBIOSOURCE INC.

Search, find, compare suppliers for anti-PAK2 (N-term), 192-222 antibody, protein, ELISA kits.

Edit 
Antigenic SpecificityPAK2 (N-term), 192-222
Clonepolyclonal
Host SpeciesRabbit
Reactive Specieshuman
Isotypen/a
Formatpurified
Size0.08 mL, 0.4 mL
Concentrationvial concentration: 1.8
ApplicationsWestern Blot (WB), ELISA (EIA), Immunohistochemistry (IHC)
Reviews / RatingsIf you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
DescriptionThis PAK2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 192-222 amino acids from the N-terminal region of human PAK2. PAK2, a member of the STE20 subfamily of Ser/Thr protein kinases, acts on a variety of targets. It phosphorylates ribosomal protein S6, histone H4 and myelin basic protein. PAK2 interacts tightly with GTP-bound but not GDP-bound CDC42/p21 and RAC1. Expression is ubiquitous, with higher levels seen in skeletal muscle, ovary, thymus and spleen. PAK2 is autophosphorylated when activated by CDC42/p21. The protein structure contains 1 CRIB domain.
Immunogenn/a
Other Names[Serine/threonine-protein kinase PAK 2; Gamma-PAK; PAK65; S6/H4 kinase; p21-activated kinase 2; PAK-2; p58; PAK-2p27; p27; PAK-2p34; p34; C-t-PAK2; PAK2]
Gene, Accession #[PAK2], Gene ID: 5062, NCBI: NP_002568.2, UniProt: Q13177
Catalog #MBS9206557
Price$165, $370
Order / More InfoPAK2 (N-term), 192-222 Antibody from MYBIOSOURCE INC.
Product Specific ReferencesBenner, G.E., et al., J. Biol. Chem. 270(36):21121-21128 (1995). Martin, G.A., et al., EMBO J. 14(9):1970-1978 (1995). Martin, G.A., et al., EMBO J. 14 (17), 4385 (1995).
MYBIOSOURCE INC.
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166

sales@mybiosource.com

http://www.MyBioSource.com

Profile of MYBIOSOURCE INC.
Return to Antibodies

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.